continued page 2....3....4.....5
Crohn'sCanada
Addressing the alarming rise of the bacterium "Mycobacterium avium Paratuberculosis"
in the environment and the growing evidence linking this bacterium to Crohn's
disease.
    Page 4
 
 

Founders: Diane and Michael Fagen

Contact Info: dianef84@yahoo.com

Home

Our Mission and our Goals

History of Crohn's Disease, Johne's disease, Mycobacterium avium Paratubercuosis

Recent Article Updates

Links to Articles
Page 2....3....4.....5

Perception of Risk

The Precautionary Principle

What is a Reportable Disease

Health of Animals Act, SC 1990, c 21

List of Reportable Diseases and REGULATIONS PRESCRIBING CERTAIN DISEASES AS REPORTABLE DISEASES

NRC National Science Library

Public Health Agency of Canada

Never In My Milk

Links

Messageboard

ree Republic/News Activism/Topics - Post Article

Research

La Presse,  April 8, 2001,  Never in My Milk? by Marie France Coutu

The Canadian Media


Canadian Medical and Government

Canadian Veterinary

Canadian Raw Milk Advocacy Group

 

Let's Talk



 

Taking Action

Link To Us

Does Mycobacterium Paratuberculosis cause Crohn's disease by Alan Kennedy  

(PARA) PARATUBERCULOSIS AWARENESS & RESEARCH ASS.,INC



Shafran's Gasterology Center

The Johne's Information Center

History of Early Research on Crohn's disease

Dr. B. Crohn

Got Milk? by Michael Greger, MD Updated January 2001

THE CROHN'S CONNECTION  by Lisa Chamberlain

Dire Warnings About Johne’s
Disease A wake-up call for the dairy industry?

Micobacteria and Crohn's Disease

Dr. Chiodini's Tables

American and European Links

University of Wisconsin School of Veterinary Medicine

Health Canada

Action Medical Research

 

University of Guelph

NACC

 

 
 
 

 

March 2007: Drug Topics: Biologic gets new indication for Crohn's disease-----Adalimumab (Humira, Abbott) is now approved for a second indication for use by patients with moderately to severely active Crohn's disease who are not responding to conventional therapy to reduce signs and symptoms and induce and maintain clinical remission.

 

 

 

2007: Antimycobacterial Therapy in Crohn’s Disease: Game Over?

 

 

July 18, 2007: Biotech Intellegence:----Australian study of anti-MAP treatment in Crohn's Disease published showing highest ever remission rates Giaconda Sydney, Australia, Giaconda Ltd (ASX: GIA) announced that the results of the first large-scale, randomized, placebo-controlled clinical study using anti-MAP therapy have been published in the journal Gastroenterology The clinical study, undertaken in 1999, was conducted prior to Giaconda acquiring the intellectual property for the anti-MAP therapy, which has now been further developed and is known as Myoconda®. The publication, titled "Two-Year Combination Antibiotic Therapy with Clarithromycin, Rifabutin and Clofazimine for Crohn's Disease", presents the results of this Phase III trial. These three active ingredients are atypical anti-mycobacterial antibiotics with unique modes of action that work on an intracellular basis and are thus referred to as anti-MAP therapy

.

 

 

Pub Med: October 1, 2007: Veterinary Microbiology Laboratory, Animal Health Division, Central Institute for Research on Goats, Makhdoom, Farah, Mathura (UP), 281 122 India.

 

Presence and characterization of Mycobacterium avium subspecies paratuberculosis from clinical and suspected cases of Crohn's disease and in the healthy human population in India

 

RENSE.COM: The Cause Of Crohn's, IBS And Most Colitis: By Jeff Rense--One of the most crucial missions of rense.com is to stop the beef and dairy poisoning - and deaths - of untold millions of Americans. The massive consumption of these 'products' leads inevitably to the countless numbers of health breakdowns and diseases...everything from cancer to heart disease to Crohn's, IBS and colitis...which are ravaging what's left of this faltering society

 

 

May 2007, Pub Med: Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion.

 

 

September 20, 2007----FOOD STANDARDS AGENCY: Control of MAP in milk: Mycobacterium avium subsp. paratuberculosis (MAP) is a bacterium that is the cause of a chronic gastrointestinal infection called Johne’s disease in cattle, and other ruminants. There have been claims that it also causes Crohn’s disease, a chronic inflammatory bowel disease of humans that can be severe, prolonged and debilitating. However, experts differ in their opinion on such a link and worldwide there is no consensus. The results of an FSA-commissioned survey which found MAP in approximately 2% of pasteurised milk on retail sale were presented to the Advisory Committee on the Microbiological Safety of Food in September 2000. As a result of the ACMSF's discussions and those of an expert group of stakeholders convened by the Agency, a strategy to control MAP in milk at all stages of the food chain has been produced and can be accessed via the link below

 

 

 

June 2007: LANDMARK CROHN'S DISEASE STUDY by Warwick Selby

  American Academy of Microbiology Colloquium: Mycobacterium avium Paratuberculosis: Infrequent human
pathogen or Public Health Threat?
 

OttawaStart, April 25, 2007: UCB Pharma Canada Launches National Scholarship Programs for Students Living With Crohn's Disease and Rheumatoid Arthritis Attaining an education is an invaluable asset for most Canadians, but one that is hard enough to obtain without dealing with a chronic illness. With the objective of making education an achievable goal for these students, UCB Pharma Canada announced today the national roll-out of the 2007 UCBeyond Crohn's Disease and Rheumatoid Arthritis Scholarship Programs.

 

 

FDA approves MyocondaR IND for MAP in Crohn's Disease: SYDNEY, Australia 24 April 2007. Giaconda Ltd (ASX: GIA) today announced that the US Food and Drug Administration (FDA) has approved the Company's Investigational New Drug application (IND) for the clinical development of MyocondaR to treat patients with Crohn's Disease infected with Mycobacterium avium spp paratuberculosis (MAP

 

 

March 19, 2007: Do Frozen Vegetables Pose A Hazard For Your Kids?

Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars T.J. Borody ., S. Bilkey, A.R. Wettstein, S. Leis, G. Pang, S. Tye Centre for Digestive Diseases, Level 1, 229 Great North Road, Five Dock, NSW 2046, Australia Received 13 September 2006; accepted 12 January 2007

 

 

 

 

Vet Microbiol. 2007 Jan 20; : 17329043 A DNA sequence capture extraction method for detection of Mycobacterium avium subspecies paratuberculosis in feces and tissue samples

 

January 2007: J Microbiol Methods.17307264 Improved template DNA preparation procedure for detection of Mycobacterium avium subsp. paratuberculosis in milk by PCR.

 

 

Pre News Wire: UCB Launches $300,000 National Scholarship Program for People Living With Crohn's Disease ATLANTA, March 1 /PRNewswire/ -- UCB, Inc. announced today the national roll out of the 2007 Crohn's Scholarship Program, which will award 30, one-time scholarships of up to $10,000 to people diagnosed with Crohn's disease who demonstrate academic ambition and who are reaching beyond the boundaries of their condition.


 

2007: Nanomedicine Research Portal: Identifying Mycobacterium avium spp. paratuberculosis (MAP), through magnetic relaxation. .........................C Kaittanis, SA Naser, JM Perez

 

 

Anti-mycobacterial in Crohn's disease heals mucosa with longitudinal scars

 

 

International Journal of Infectious Diseases: Presence of characterization of Mycobacterium avium subspecies
paratuberculosis from clinical and suspected cases of crohn's disease and in the healthy human population in
India

 

 

November 2006:The Scotsman Newpaper: Crohn's disease vaccine breakthrough announced KURT BAYER

 

 

Mcgill University Center: Visualization of Mycobacterium avium in Crohn's tissue by Oil-Immersion Microscopy

 

Mcgill University Center: The Evidence for Mycobacterium paratuberculosis in Crohn's Disease, by Marcel Behr
M.D. and Vivek Kapur

 

 


 

Newspaper Article, Tuesday, February 14, 2006, Daily Mail, Vaccine To End Crohn's Misery for Thousands, by Martyn Halle

 

January 2006, INFLAMMATORY BOWEL DIS: Specific antibodies against recombinant protein of insertion element 900 of Mycobacterium avium subspecies paratuberculosis in Japanese patients with Crohn's disease. BACKGROUND: Mycobacterial avium subspecies paratuberculosis (MAP) infection has been hypothesized as an etiological factor of Crohn's disease (CD). However, the involvement of MAP in the pathophysiology of CD is controversial. The aim of this study is to investigate whether MAP is involved in the pathogenesis of CD with the glutathione S-transferase fusion recombinant protein encoding a portion of insertion element (IS) 900 (IS900-GST), which is specific for MAP.

 

 

 

Integrating theories of the etiology of Crohn’s Disease: ...........On the etiology of Crohn’s Disease: Questioning the Hypotheses William M. Chamberlin1, Saleh A. Naser2 © Med Sci Monit, 2006; 12(2): RA27-33 PMID: 16449960

 

 
 
 

 

Mycobacterium avium ssp. paratuberculosis in foods: current evidence and potential consequences International Journal of Dairy Technology 59 (2), 112–117. doi:10.1111/j.1471-0307.2006.00248.x

 

 

 

The New DNA Crohns Vaccine Summary 2006 , Please send donations to:

Professor John Hermon-Taylor Department of Surgery St George’s, University of London London SW17.0RE, UK. Tel: 020 8767 7631 Fax: 020 8725 5582 Email : jhermon@sgul.ac.uk

 

November 14, 2006: CROHN'S AND COLITIS FOUNDATION: Study Reports Discovery of New Genetic Link to Crohn’s Disease,,,,,,,,,,,,,,,,,,,,A group of North American researchers from leading digestive disease institutes, including the University of Toronto, have released the findings of a large-scale study indicating a new genetic link to Crohn’s disease, which is considered a positive breakthrough in finding a cure for the disease.

 

Mycobacterium avium ssp. paratuberculosis in foods: current evidence and potential consequences IRENE R GRANT*

 

March 16, 2006. Red Orbit:: Doctor: Infection is at root of Crohn's disease by Delthia Ricks, Staff Writer, ...................................In the tradition of an Australian Nobel-Prize winner who bucked the establishment, another doctor from down under insists Crohn's disease, an inflammatory bowel disorder, is caused by renegade microbes

   
 


 

FOOD STANDARDS ASSOCIATION: Control of MAP (Mycobacterium avium subsp. paratuberculosis) in milk. JANUARY 1, 2006. FOOD HYGIENE LEGISLATION CHANGES.

 

 

 

Development of improved method for isolation of Mycobacterium avium subsp. paratuberculosis from bulk tank milk: Effect of age of milk, centrifugation, and decontamination Anli Gao, Joseph dumeru, Melinda Raymond, and Lucy Mutharia

 

 

2006 Foodborne Pathog Dis. ;3 (4):457-60 17199528 Modified Culture Protocol for Isolation of Mycobacterium avium subsp. paratuberculosis from Raw Milk.

 

 

 

 

November 25/05: A New Paradigm For Crohn's Disease: A Call to Action

 

2005: Mycobacterium avium paratuberculosis in Crohn’s: a study using tissue PCR, in situ PCR and interferon-.. responses Marcel A. Behr, MD Makeda Semret, MD Background • M. avium paratuberculosis (MAP): emerging pathogen, cause of IBD in cattle and other animals • Histopathological similarities between certain types of paratuberculosis (sheep paucibacillary) and Crohn’s disease • Issues in proving link between MAP and Crohn’s: – Technical: accurate diagnostic tests – Conceptual: study design • Case definition/classification of Crohn’s disease • Appropriate controls (PDF)

 

 

Journal of Clinical Microbiology, March 2004: Population-Based Case Control Study of Seroprevalence of Mycobacterium paratuberculosis in Patients with Crohn's Disease and Ulcerative Colitis Charles N. Bernstein,1,2,* James F. Blanchard,1,3 Patricia Rawsthorne,1,2 and Michael T. Collins4

 

 

GUT July 2005

High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease.

 

September, 2004: Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease

 

Unraveling the mystery of Crohn's disease: .................Could bacteria found in dairy products play a key role in Crohn's disease? By Patrick Perry Published: March/April 2004

 

 

 

Lancet, September 2004: Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease

 

 

Crohn's and Colitis Foundation: Researchers Measure Rate of Crohn's and Colitis in Manitoba Spring 2000
Drs. C Bernstein; Blanshard J The Journal, CCFC

 

 

 

 

Journal of Clinical Biology: Population-Based Case Control Study of Seroprevalence of Mycobacterium paratuberculosis in Patients with Crohn's Disease and Ulcerative Colitis Charles N. Bernstein1,2,*, James F. Blanchard1,3, Patricia Rawsthorne1,2 and Michael T. Collins4

 

 

 

November, 2003: IBDanswers: DrugTopics: Crohn's: An Infectious Disease? Australia. Thomas Borody, M.D., director of the Centre for Digestive Diseases, utilizes triple antimycobacterial therapy for his Crohn's patients. Borody said he uses a combination of rifabutin (Mycobutin, Pharmacia), clarithromycin (Biaxin, Abbott), clofazimine (Lamprene, Novartis), and ethambutol for at least three years in his Crohn's disease patients. In his experience, "cures are achieved in 20%-25% of patients and the rest go into total remission." By cure, he means that when his patients are off all medications, they not only have no symptoms, but, endoscopically, they have no inflammation, no histologic evidence of Crohn's disease, and their blood work is negative for markers of inflammation.

 

 

BREAKING NEWS: FOR IMMEDIATE RELEASE CONTACT: Kelly Alpert Vest Suffolk Y Jewish Community Center (631)462-9800 Ext 142 (631)462-9462 kvest@syjcc.org www.suffolkyjcc.org Professor Thomas Borody of Australia comes to New York to discuss significant new findings in the fight against Crohn's Diseas

 

 

 



 

Continued Page ......5

 








www.crohnscanada.org ~ MAP-Canada ~ MAP-Canada@crohnscanada.org

Disclaimer:
MAP-Canada does not advocate a particular cause of Crohn's disease.  Our website is intended only to present evidence.  Our readers may draw their own conclusions.  We are not medical specialists and do not offer any treatment or nutritional advice.  Our mission is not to lay blame on any individual or industry, but rather to urge the Government of Canada to address the evidence presented on this site.

Mise au Point:
MAP-Canada ne recommande aucune théorie particulière sur la cause de la maladie de Crohn.L'intente de notre site Web est simplement de présenter certaineévidence mais vous pouvez arriver à vos propres conclusions.Nous ne pouvons donner de conseils de nature médicale ou alimentaire. Notre mission ne consiste aucunement à blâmer un individuou une industrie mais
plutôt à s'assurer que le Gouvernement du Canada aborde l'évidence que nous présenton

MAP-Canada would like to extend a very sincere thank you to Yanik Chicoine at www.mirweb.com for his generosity and assistance in the hosting and the mounting of this site.

MAP-Canada aimerait remercier sincèrement Yanik Chicoine a www.mirweb.com pour sons générosité et sons assistance pour l'hébergement et la programation du site.



continued page 2....3....4.....5